Last updated: 11/07/2018 16:29:44
A post-marketing surveillance study of subject-reported adverse events rates for Malarone (atovaquone and proguanil), mefloquine and chloroquine/proguanil, when used for prophylaxis for travel up to 28 days maximum
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A post-marketing surveillance study of subject-reported adverse events rates for Malarone (atovaquone and proguanil), mefloquine and chloroquine/proguanil, when used for prophylaxis for travel up to 28 days maximum
Trial description: A post-marketing surveillance study of subject-reported adverse events rates for Malarone (atovaquone and proguanil), mefloquine and chloroquine/proguanil, when used for prophylaxis for travel up to 28 days maximum
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Post-marketing surveillance: adverse events during long-term use of atovaquone/proguanil for travelers to malaria-endemic countries. Overbosch, D. J Travel Med 2003; 10 Suppl 1(S16-20); discussion S21-3
Medical condition
Malaria
Product
atovaquone/proguanil
Collaborators
Not applicable
Study date(s)
August 2002 to Invalid Date
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Clinical study report
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
Not applicable
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website